What is AstraZeneca?
Science-led biopharmaceutical company discovering, developing, and commercializing prescription medicines in oncology, rare diseases, and biopharmaceuticals.
- Category
- Pharmaceuticals & Biopharmaceuticals
- Headquarters
- Cambridge Biomedical Campus, Cambridge, UK
- Founded
- April 6, 1999 (Astra AB × Zeneca merger)
- Employees
- ~95,100 (Dec 31, 2025)
- Total Revenue (FY2025)
- $58.7 billion (+9% reported; +8% CER)
- Market Capitalization
- ~$277–316 billion (June 2026, NYSE/LSE: AZN)
What is AstraZeneca?
AstraZeneca is a global, science-led biopharmaceutical company that discovers, develops, manufactures, and commercializes prescription medicines across oncology, rare diseases, cardiovascular/renal/metabolism (CVRM), and respiratory and immunology. Headquartered at the Cambridge Biomedical Campus in the UK and publicly listed on the London Stock Exchange, Nasdaq Stockholm, and the New York Stock Exchange (ticker: AZN on all three), the company generated $58.7 billion in total revenue in FY2025 and employs approximately 95,100 people in over 100 countries.
Formed on April 6, 1999 through a £23 billion merger of Sweden's Astra AB (founded 1913) and the UK's Zeneca Group PLC (carved out of ICI in 1993), AstraZeneca has transformed from a broadly diversified pharmaceutical company into a focused biopharmaceutical powerhouse. The architect of that transformation is CEO Pascal Soriot, who joined in October 2012 from Roche/Genentech and systematically divested non-core assets while doubling down on oncology, biologics, and rare disease science.
Its oncology business unit — anchored by blockbusters Tagrisso ($7.25B in 2025), Farxiga ($8.4B), Imfinzi ($6.1B), Calquence ($3.5B), and Enhertu ($2.8B AstraZeneca share) — generated $25.6 billion in 2025 product revenue and is among the fastest-growing oncology franchises in the industry, up 18% at constant exchange rates year-on-year. The rare disease franchise, built around the $39 billion acquisition of Alexion Pharmaceuticals (completed July 2021), added a third pillar anchored by Soliris and Ultomiris for complement-mediated disorders.
AstraZeneca now counts 16 blockbuster medicines (products exceeding $1 billion in annual sales), a pipeline of 197 projects in development, and a stated $80 billion revenue ambition by 2030 — supported by a $50 billion commitment to US manufacturing and R&D announced in July 2025. It is consistently among the top-three most valuable companies in the UK and ranked 59th globally by market cap as of mid-2026.
What does AstraZeneca offer?
AstraZeneca's product portfolio spans five core therapy areas with 16 blockbuster medicines generating over $1 billion each in annual sales, plus a 197-project pipeline including ADCs, biologics, small molecules, cell therapies, and next-generation genomics-informed targets.
- Tagrisso (osimertinib) — $7.25B (2025)· Oncology
- Farxiga/Forxiga (dapagliflozin) — $8.4B (2025)· Cardiovascular, Renal & Metabolism
- Imfinzi (durvalumab) — $6.1B (2025)· Oncology
- Calquence (acalabrutinib) — $3.5B (2025)· Oncology
- Lynparza (olaparib) — $3.3B (2025)· Oncology
- Enhertu (trastuzumab deruxtecan) — $2.8B AZ share (2025)· Oncology
- Ultomiris (ravulizumab)· Rare Disease
- Soliris (eculizumab)· Rare Disease
- Brilinta/Brilique (ticagrelor)· Cardiovascular, Renal & Metabolism
- Beyfortus (nirsevimab)· Vaccines & Immune Therapies
- Breztri/Trixeo (budesonide/glycopyrrolate/formoterol)· Respiratory & Immunology
- Fasenra (benralizumab)· Respiratory & Immunology
- Antibody-Drug Conjugates (ADCs)· Next-Generation Therapeutics
- Cell Therapy· Next-Generation Therapeutics
- AI-Enabled Drug Discovery (Centre for Genomics Research)· Platform Technology
- Oral GLP-1 / Weight Management Pipeline· Pipeline
How does AstraZeneca make money?
AstraZeneca earns revenue primarily through product sales of prescription medicines — priced via negotiated contracts with payers, pharmacy benefit managers (PBMs), government health systems, and hospitals — supplemented by collaboration milestones and royalties from co-development partnerships. Product sales account for approximately 99% of total revenue ($58.6B of $58.7B in FY2025).
In the United States — the structurally most important market, where AstraZeneca targets roughly 50% of its $80B 2030 revenue — prices are set at a Wholesale Acquisition Cost (WAC) list price, then negotiated down through PBM rebates, Medicaid best-price rules, and 340B program discounts. Internationally, reimbursement is determined via Health Technology Assessment (HTA) bodies such as NICE in the UK and HAS in France. The Inflation Reduction Act's Medicare drug price negotiation provisions represent an ongoing headwind for US pricing on mature blockbusters like Farxiga.
Key blockbuster drugs function as standalone revenue engines. Farxiga, AstraZeneca's top-selling product, reached $8.4B in 2025 sales (+9% CER), driven by expanding indications in heart failure and chronic kidney disease. Tagrisso contributed $7.25B (+10% CER) in lung cancer. Enhertu — a co-developed ADC with Daiichi Sankyo — delivered $2.8B of AstraZeneca's P&L share (+40% CER), with AZ recording its portion of co-promotion profits plus milestones and royalties. Imfinzi (durvalumab) reached $6.1B (+29% CER), boosted by the LAURA lung cancer approval. The Oncology business unit generated $25.6B in 2025 product revenue, representing 44% of the total and growing 18% CER.
R&D investment runs at roughly 23–25% of revenue ($13–15B annually), funding a 197-project pipeline. The company delivered a 31% core operating margin in FY2025 (core operating profit ~$18B) and core EPS of $9.16 (+11% CER), targeting a mid-to-high single-digit revenue growth in 2026 and a mid-30s% core operating margin by 2026. There is no SaaS or subscription pricing model; growth is driven by new patient volume, label expansions, geographic expansion into emerging markets, and pipeline launches — with management guiding for 20 new medicine approvals by 2030.
Who leads AstraZeneca?
AstraZeneca is led by CEO Pascal Soriot, who has helmed the company since October 2012 and orchestrated its transformation into a leading oncology and biopharmaceutical powerhouse. The Senior Executive Team (SET) spans oncology, biopharmaceuticals, rare disease, operations & IT, finance, and R&D.
- Pascal SoriotChief Executive OfficerOctober 2012 – presentFormer COO of Roche Pharmaceuticals and CEO of Genentech; architect of AstraZeneca's oncology-led transformation, the $39B Alexion acquisition, and the $80B 2030 revenue ambition.
- Aradhana SarinChief Financial OfficerAugust 2021 – presentMedical doctor (University of Delhi) turned banker; former CFO of Alexion prior to acquisition; held senior roles at Citi, UBS, and JP Morgan. Member of the Board.
- Dave FredricksonEVP, Oncology Business Unit2017 – presentLeads the oncology commercial engine that generated $25.6B in 2025 product revenue, including blockbusters Tagrisso, Enhertu, Imfinzi, Calquence, and Lynparza.
- Ruud DobberEVP, BioPharmaceuticals Business UnitJanuary 2019 – presentOversees cardiovascular/renal & metabolism (CVRM) and respiratory & immunology commercial operations globally, plus vaccines & immune therapies.
- Susan GalbraithEVP, Oncology Haematology R&D2013 – presentLeads the oncology R&D pipeline, including ADC programs (Enhertu, datopotamab deruxtecan), PARP inhibitors, and immuno-oncology combination strategies.
- Sharon BarrEVP, BioPharmaceuticals R&DAugust 2023 – presentSucceeded Sir Mene Pangalos upon his retirement after 14 years. Previously SVP and Head of Research & Product Development at Alexion. Leads R&D for cardiovascular, respiratory, and immunology programs.
- Pam ChengEVP, Global Operations & IT; Chief Sustainability OfficerJune 2015 – present (Board member from April 2025)Leads 22,000+ colleagues across manufacturing, supply chain, procurement, IT, and sustainability in 18 countries. Oversees the Axial SAP S/4Hana transformation program.
- Iskra ReicEVP, InternationalDecember 2024 – present (joined AZ 2001)Oversees all international commercial markets outside the US. Previously EVP, Europe & Canada; joined company in 2001 with leadership roles across CEE, Eurasia, MEA.
How do you contact AstraZeneca's leadership?
AstraZeneca's verified corporate email format is firstname.lastname@astrazeneca.com (used by ~94% of employees per RocketReach). No personal executive emails are publicly published; addresses below follow the verified format for leadership, with published functional addresses for media and investor relations.
firstname.lastname@astrazeneca.comHow much funding has AstraZeneca raised?
AstraZeneca is a publicly traded company (LSE: AZN, NYSE: AZN, Nasdaq Stockholm: AZN) and does not raise venture or private equity funding. Its capital structure is supported by equity markets, investment-grade debt issuances, and robust retained earnings; its market capitalization was approximately $277–316 billion as of June 2026, making it one of the most valuable pharmaceutical companies in the world.
AstraZeneca has been continuously publicly listed since the April 1999 merger of Astra AB (Stockholm Stock Exchange, founded 1913) and Zeneca Group PLC (London Stock Exchange, spun out of ICI in 1993). The company added NASDAQ American Depositary Receipts (ADRs) in 2001 for US investor access and in February 2026 completed a landmark harmonisation: ordinary shares listed directly on the NYSE (ticker AZN), replacing the two-for-one ADS structure. AstraZeneca is now simultaneously listed on three exchanges — LSE, Nasdaq Stockholm, and NYSE — one of the first large-cap European pharma companies to achieve this structure.
The largest single capital deployment in company history was the $39 billion all-cash-and-stock acquisition of Alexion Pharmaceuticals (announced December 2020, closed July 21, 2021), funded through multi-tranche investment-grade bond issuances, bridge facilities, and available cash. Alexion shareholders received $60 in cash plus 2.1243 AstraZeneca ADS shares, valuing Alexion at approximately $175 per share. In November 2024 AstraZeneca announced a $3.5 billion US investment tranche, followed by a far larger $50 billion US manufacturing and R&D commitment announced July 21, 2025 — the largest US capital commitment in AstraZeneca's history — covering new manufacturing sites in Virginia, Indiana, California, Maryland (Rockville), and Massachusetts (Kendall Square).
In terms of financial performance, AstraZeneca has grown revenue from approximately $26 billion in 2019 to $58.7 billion in FY2025, a compound annual growth rate of approximately 14%. The company delivered a 31% core operating margin in FY2025 (core operating profit ~$18 billion) and core EPS of $9.16 (+11% CER). The full-year 2025 dividend was $3.20 per share (+3% year-on-year), and the company maintains an investment-grade credit rating that enables continued large-scale debt financing at competitive rates.
How did AstraZeneca get here?
AstraZeneca was formed in 1999 from the merger of two European pharmaceutical companies and has since undergone a dramatic strategic transformation — from a broad, generics-facing portfolio to a focused oncology and biopharmaceuticals powerhouse with $58.7 billion in 2025 revenue and an $80 billion target for 2030.
- April 6, 1999AstraZeneca founded via £23B merger of Astra AB and Zeneca GroupThe merger of Sweden's Astra AB (est. 1913, Stockholm-listed) and the UK's Zeneca Group PLC (ICI spin-out, London-listed since 1993) created one of Europe's largest pharmaceutical companies, jointly listed on the London Stock Exchange and Nasdaq Stockholm.
- October 2012Pascal Soriot appointed CEO; oncology-led transformation beginsFormer Roche COO and Genentech CEO Pascal Soriot takes the helm and launches a multi-year strategy to divest non-core assets (PPIs, cholesterol, psychiatric drugs) and double down on oncology, CVRM, and respiratory science.
- December 2020COVID-19 vaccine Vaxzevria co-developed with Oxford University authorized in UKThe adenoviral vector vaccine received its first emergency authorization in December 2020 and was ultimately delivered to more than 180 countries — approximately two-thirds going to low- and middle-income nations — establishing AstraZeneca's global public health credentials.
- July 21, 2021Alexion Pharmaceuticals acquisition completed for $39 billionThe largest acquisition in AstraZeneca's history created Alexion, AstraZeneca Rare Disease, bringing Soliris, Ultomiris, and the complement-biology platform into the portfolio. Alexion shareholders received $60 cash plus 2.1243 AstraZeneca ADS per share (~$175/share total consideration).
- May 2024Ambition 2030 announced: $80 billion revenue target, 20 new medicinesAt its Investor Day, AstraZeneca unveiled a plan to launch 20 new medicines by 2030, achieve 25+ blockbusters, and reach $80 billion in total revenue — roughly doubling 2023 revenue of ~$45 billion within seven years, with ~50% from the United States.
- December 4, 2025Salesforce Agentforce Life Sciences selected as global CRM, replacing VeevaAstraZeneca selected Salesforce's Agentforce Life Sciences for Customer Engagement as its unified global CRM platform — described as one of the largest Veeva departures in the pharmaceutical industry — to drive AI-powered healthcare professional engagement across oncology and biopharmaceuticals.
- February 2, 2026AstraZeneca lists ordinary shares directly on NYSE, replacing NASDAQ ADRsAstraZeneca achieved a harmonized triple listing on LSE, Nasdaq Stockholm, and the NYSE (ticker AZN), replacing its prior two-for-one ADS structure. This broadens direct US investor access and supports the company's US revenue growth strategy for 2030.
Who are AstraZeneca's competitors?
AstraZeneca competes across oncology, cardiovascular, rare disease, and respiratory with the other top-ten global pharmaceutical companies. In oncology — its largest segment — the primary rivals are Merck (MSD), Roche/Genentech, Bristol-Myers Squibb, and Pfizer. In CVRM and respiratory, competitors include Novo Nordisk, Johnson & Johnson, Novartis, and GSK. In rare disease, Sanofi/Genzyme is the nearest competitor.
- PfizerBroad-based pharma giant; Seagen ADC portfolio (Padcev, Tukysa) competes with Enhertu in HER2+ cancers; co-promotes Eliquis (BMS) in cardiovascular; oncology pipeline competes across solid tumors and hematology.
- RocheHistorically dominant oncology franchise via Herceptin, Avastin, and Tecentriq; competes head-on with Tagrisso in lung cancer and Enhertu's HER2 franchise through Kadcyla/biosimilars; strong diagnostics moat and HER2 companion diagnostic overlap.
- MerckKeytruda (~$25B+ in annual sales) is the world's top-selling oncology drug and directly competes with Imfinzi, AstraZeneca's PD-L1 inhibitor, across lung, bladder, and endometrial cancers.
- Bristol-Myers SquibbOpdivo + Yervoy immuno-oncology franchise competes with AstraZeneca's Imfinzi/Imjudo combination; Eliquis competes with Brilinta in the antiplatelet/anticoagulant cardiovascular space.
- NovartisOncology portfolio (Kisqali in HR+/HER2- breast cancer, Kymriah CAR-T) and cardiovascular (Leqvio PCSK9, Entresto) compete with AstraZeneca's CVRM drugs; Sandoz biosimilars target off-patent AZ products.
- GSKUK-headquartered rival with overlapping respiratory (Nucala, Trelegy Ellipta) and oncology (Zejula PARP inhibitor, Jemperli) programs; Coreg and other cardiovascular assets compete in CVRM; also competes in vaccine/immune therapy space via Shingrix and RSV programs.
AstraZeneca — frequently asked questions
